References
- National Institute of Mental Health. Bipolar Disorder. NIH Publication No. 12-3679. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2012. http://www.nimh.nih.gov/health/publications/bipolar-disorder/index.shtml. Accessed March 6, 2015
- Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
- Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
- Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139-54
- Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004;6:368-73
- Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 2005;67:1-8
- Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry 2003;160:1286-90
- Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 2011;129:79-83
- Parikh SV, Kusumakar V, Haslam DR, et al. Psychosocial interventions as an adjunct to pharmacotherapy in bipolar disorder. Can J Psychiatry 1997;42(2 Suppl):74S-8S
- National Institute of Mental Health. Schizophrenia. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2009. http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. Accessed December 27, 2013
- Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007;13:S178-88
- Strakowski SM, Del Bello MP, Adler CM, et al. Atypical antipsychotics in the treatment of bipolar disorder. Expert Opin Pharmacother 2003;4:751-60
- Bergeson JG, Kalsekar I, Jing Y, et al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits 2012;5:379-86
- Kim E, You M, Pikalov A, et al. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. BMC Psychiatry 2011;11:6
- Stender M, Bryant‐Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther 2002;24:1668-76
- Pelletier E, Hassan M, Alemayehu B, et al. Bipolar disorder healthcare costs for quetiapine extended-release versus aripiprazole. Am J Pharm Benefits 2013;5:e73-9. http://www.ajmc.com/publications/ajpb/2013/ajpb_mayjun2013/bipolar-disorder-healthcare-costs-for-quetiapine-extended-release-versus-aripiprazole). Accessed February 10, 2015
- Schoemaker J, Stet L, Vrijland P, et al. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry 2012;45:196-203
- Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30:106-15
- Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84
- D'Hoore W, Bouchaert A, Tilquin C. Practical consideration on the use of the Charlson comorbidity index with administrative databases. J Clin Epidemiol 1996;49:1429-33
- Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8
- Bureau of Labor Statistics. Consumer Price Index, U.S. Bureau of Labor Statistics, Washington DC, 2013. http://www.bls.gov/cpi/. Accessed December 27, 2013
- Depression and Bipolar Support Alliance (DBSA). Bipolar disorder statistics. Chicago, IL: Depression and Bipolar Support Alliance (DBSA), 2000. http://www.dbsalliance.org/site/PageServer?pagename=education_statistics_bipolar_disorder. Accessed May, 2015
- Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv 2011;62:1032-40
- Chen W, Deveaugh-Geiss AM, Palmer L, et al. Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. Hum Psychopharmacol 2013;28:428-37
- Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 2002;4:398-405
- Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord 2002;69:109-18
- National Alliance on Mental Illness. The impact and cost of mental illness: the case of bipolar disorder. Arlington, VA: National Alliance on Mental Illness (NAMI), 2015. http://www2.nami.org/Template.cfm?Section=bipolar_disorder&template=/ContentManagement/ContentDisplay.cfm&ContentID=42734. Accessed March 6, 2015
- Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness–1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-9
- Newman CF. Bipolar Disorder (Chapter 15). In: Andrasik F, ed. Comprehensive Handbook of Personality and Psychopathology, Adult Psychopathology. Vol 2. Hoboken, NJ: John Wiley & Sons, Inc., 2005. pp. 244-57
- Lang K, Korn J, Muser E, et al. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ 2011;14:217-26